Source comparison
Mechanism of Action: Peptide vs Small Molecule
MOTS-c functions as a retrograde signaling molecule. It's encoded within mitochondrial DNA (specifically the 12S ribosomal RNA gene) and synthesized inside mitochondria, but under metabolic stress conditions like glucose restriction or oxidative challenge, it
This comparison does not assign a generated winner or score.
- MOTS-c functions as a retrograde signaling molecule. It's encoded within mitochondrial DNA (specifically the 12S ribosomal RNA gene) and synthesized inside mitochondria, but under metabolic stress conditions like glucose restriction or oxidative challenge, it translocates to the cell nucleus. Once there, it binds to nuclear DNA and activates transcription of genes involved in insulin sensitivity, antioxidant response (via Nrf2 pathway activation), and folate-methionine cycle regulation. Research published in Cell Metabolism demonstrated that MOTS-c administration in mice improved glucose tolerance by 25–30% and prevented age-related insulin resistance without altering food intake. The mechanism is metabolic reprogramming at the gene expression level. Not appetite suppression.
- Tesofensine operates through competitive inhibition of monoamine transporters. It has approximately equal affinity for the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT). With IC50 values around 6–8 nM for all three. By blocking reuptake, it prolongs the availability of these neurotransmitters in synaptic clefts, which amplifies signaling in brain regions that regulate reward, arousal, and satiety. The result is a dose-dependent reduction in ad libitum food intake. Clinical trials showed 0.5mg daily reduced caloric intake by roughly 20%, while 1.0mg reduced it by 30%. Critically, Tesofensine does not alter basal metabolic rate or energy expenditure. Weight loss is driven entirely by reduced intake.
- The structural difference matters for research design. MOTS-c is a short peptide (16 amino acids, molecular weight ~1,675 Da) requiring subcutaneous or intraperitoneal injection with careful cold-chain storage. Tesofensine is a lipophilic small molecule (molecular weight ~274 Da) with oral bioavailability around 80% and a half-life of 7–8 days, allowing once-weekly dosing in some protocols. MOTS-c degrades rapidly in serum (half-life under 30 minutes without stabilization), so timing relative to metabolic challenges is critical. Tesofensine accumulates with repeated dosing due to its long half-life, making steady-state plasma concentrations the relevant metric. Not peak levels.